Dr. Talha Badar, MD

Dr. Badar practices at Mayo Clinic Hospital in Jacksonville, Florida, part of Mayo Clinic.

Dr. Badar's NPI, 1760818959, was assigned on September 19, 2013. Dr. Badar graduated from Jinnah Medical and Dental College in 2004. Dr. Badar holds Florida license 146204.

Dr. Badar's primary practice is Mayo Clinic Hospital, at 4500 San Pablo Rd, Jacksonville, FL 32224 in Duval County. The practice phone is (904) 953-2000.

Dr. Badar's primary practice is Mayo Clinic Hospital in Jacksonville, Florida, part of Mayo Clinic. The medical group on file is Mayo Clinic Jacksonville.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Badar practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Badar's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Badar is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Badar's licenses on file in 2 states: Florida and Wisconsin.

Dmand AI lists arterial blot clot /embolism, chronic anemia, chronic leukemia, colorectal cancer, fluid and electrolyte imbalances, immune deficiency disease, lung cancer and lymphoma among the conditions Dr. Badar treats.

CMS data shows 79,867 Medicare services from Dr. Badar across 56 procedure codes in 2024, for 838 Medicare patients. Medicare paid $1,337,746 for them.

CMS counts 838 Medicare patients who saw Dr. Badar in 2024. The largest group is 65 to 74, with 406 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 4% are also on Medicaid. Their average risk score is 2.71, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Badar's median patient age at 68, with 48% women.

In 2024, Dr. Badar wrote 521 Medicare Part D claims for 95 patients. 62% of them were for generic drugs. CMS names the drug for 387 of them, across 17 drugs with 11 or more claims each, at $2,659,857 in total drug cost. In 2023, CMS named 257 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Badar for performance year 2024, reported as part of a group. Dr. Badar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Badar as offering telehealth.

Dmand AI links 115 papers to Dr. Badar, published from 2014 to 2025. 2023 was the busiest year, with 25. The most frequent topics are Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation and Myelodysplastic Syndromes. Dr. Badar has published most often in Am J Hematol. Dr. Badar's most frequent co-authors are James M. Foran, MD, Naseema Gangat, MBBS and Aref Al-Kali, MD.

Dmand AI links Dr. Badar to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute and Leukemia, Myeloid.

CMS Open Payments shows 43 general payments to Dr. Badar from 16 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 67% of the total. Syndax Pharmaceuticals, Inc. paid the most, $8,752.

Dr. Badar graduated from Jinnah Medical and Dental College in 2004.

Dr. Badar is in network with 9 carriers, including Blue Cross Blue Shield of Michigan, United Healthcare and Aspirus Health Plan. PPO plans come from the most carriers, 4. Check the plan with the practice before a visit.